6 Results for "

Ex19del

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "Ex19del" in MCE Product Catalog:

Cat. No.: HY-138072
CAS No.: 35773-42-3
Purity:  99.78%
Target:  

EGFR

Research Areas:  

Cancer

EMI1 is an EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-164392
CAS No.: 1451370-01-6
Target:  

EGFR Apoptosis

Research Areas:  

Cancer

TAS-121 is an orally active, selective, covalent, third-generation mutant EGFR-tyrosine kinase inhibitor (EGFR-TKI). TAS-121 inhibits the L858R mutation (IC50=1.7 nM), Ex19del mutation (IC50=2.7 nM), L858R/T790M mutation (IC50=0.56 nM) and Ex19del/T790M mutation (IC50=1.1 nM) and wild-type EGFR (IC50=8.2 nM). TAS-121 inhibits HER2 and HER4 with IC50s of 110 and 2.6 nM, respectively. TAS-121 inhibits phosphorylation of EGFR and its downstream signaling targets to block cell proliferation. TAS-121 induces apoptosis and displays antitumor activity in SW48 (EGFR G719S) and NCI-H1975 (EGFR L858R/T790M) xenograft models .
loading...
    loading...
Cat. No.: HY-131067
CAS No.: 2414374-41-5
Purity:  99.72%
Target:  

EGFR

Research Areas:  

Cancer

EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants .
loading...
    loading...
Cat. No.: HY-128860
CAS No.: 2050906-97-1
Target:  

EGFR

Research Areas:  

Cancer

Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=<1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity .
loading...
    loading...
Cat. No.: HY-131066
CAS No.: 34564-13-1
Purity:  99.02%
Target:  

EGFR

Research Areas:  

Cancer

EMI48, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI48 inhibits EGFR triple mutants .
loading...
    loading...
Cat. No.: HY-183682
CAS No.: 3101563-22-5
Target:  

EGFR p38 MAPK ERK Akt

Research Areas:  

Cancer

AZ14289671 is an orally active, blood-brain barrier-penetrant tyrosine kinase (tyrosine kinase) inhibitor (TKI) that specifically targets non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (EGFR Exon20Ins), while largely sparing wild-type EGFR to reduce off-target toxicities such as rash and diarrhea. AZ14289671 inhibits the downstream MAPK/ERK/AKT pathway, suppressing tumor cell proliferation, survival and migration. AZ14289671 can be used for NSCLC research .
loading...
    loading...